Avifavir® is the first effective drug for COVID‐19 treatment registered in Russia

AVIFAVIR®

ANTI COVID-19 THERAPY

Avifavir is the first Favipiravir-based drug in the world approved for the treatment of COVID-19. Favipiravir-based drugs have demonstrated efficacy in three independent clinical trials in Russia involving more than 700 patients with confirmed cases of COVID-19, as well as in trials conducted in Japan and other countries. The European Medical Alliance is the authorized representative of the Russian pharmaceutical company Chromis LLC, a joint venture (JV) of the Russian Direct Investment Fund (RDIF), the Russian State Welfare Fund, with the ChemRar Group, aimed at the production of Avifavir® and other related innovative antiviral drugs.Together with our founders, we represent interests in the regions of Europe, Latin America, Asia and Africa.

Benefits in everything

FOR PATIENTS

- efficient and safe
- both in hospitals and at home
- prevention of hospitalization
- faster recovery
- reduced contagiosity and isolated period
- convenient per os

FOR DOCTORS

- no fear of COVID-19
- decreased burden on hospitals by 3 times
- reduced hospitalization period by 30

FOR ECONOMY

- reduced social tensions
- reduced disability period
- support of economy
- prevention of lockdown

Avifavir® status by today

A brief history of the development of Avifavir® in the period 2020-2021 Today Avifavir® is registered in 15 countries of the world. The situation changes daily. Avifavir® has entered the international market and the European Medical Alliance is actively involved in this.

AVIFAVIR®

status by today

MAY 2020

Emergency Use Authorization obtaining via fast-track on 60 patients

JUNE 2020
AUGUST 2020
OCTOBER 2020
NOVEMBER 2020
MARCH 2021

AVIFAVIR®

advantages

Avifavir® advantages

Fully developed and scaled technology of API and DP manufacturingHigh quality of the product: 2 years stabilityProprietary IPClinical results efficacy in COVID-19 treatment 460 patients in 35 medical centers of Russia took part in clinical trials (phase II / III) of Avifavir®Fast supply of drug products to any destination 600 000+ packs per month manufacturing at 3 sites in RussiaOption for technology transfer to local partner for a long-term collaborationCompetitive pricing

Experts’ opinions

The drug proved to be highly effective during the clinical trials involving I.M. Sechenov First Moscow State Medical University, Lomonosov Moscow State University and other medical and academic institutions.Avifavir was first developed and licensed as commercial drug by ChemRar Group with the support of the Russian Direct Investment Fund and the Ministry of Industry and Trade of Russia. The permanent Marketing Authorization was obtained based on the clinical trial data covering 460 patients, which proved the drug’s ability to block the replication mechanisms of coronavirus, alleviate symptoms and reduce the duration of the disease by half compared to the conventional therapy. This clinical trial has been conducted in 35 medical centers across Russia.

The entire presentation

Within the shortest term possible, the ChemRar specialists developed testing platforms and a set of methods for the synthesis of substances and pharmaceutical formulation. On May 29th, 2020, after all the pre-clinical and clinical studies were completed, the medicine was registered and became available to patients.We present to your attention the presentation of Avifavir. If necessary, you can download our files and read them in more detail. We have selected all the answers to your questions.

Description in PDF files

For your convenience, you can view the presentation files in any browser without downloading them. To download files to your device, you need to click the arrow in the right corner, enlarge the file and download from our file store.

PRESENTATION AVIFAFIR

Read / download

FOR MEDICAL USE OF AVIFAVIR

Read / download

SCIENCE SPOTLIGHT AVIFAFIR

Read / download

ABOUT CHEMRAR GROUP

Read / download

INFORMATION LETTER

Read / download

BRIEFING
NOTE

Read / download

Acquisition of Avifavir and cooperation with us

We are interested in working with public and private companies to promote Avifavir worldwide.

AVIFAVIR®

Our instructions in 4 steps

The first step

Read the description of Avifavir in our introductory presentations.

The second step
The third step
The final step

About Us

EurMA®

www.eurma.eu

Summary

We are professional corporate consultants specializing in healthcare, pharmaceutical and medical technology companies. We analyze markets, plan new product launches and support investment decisions in the CIS and Central Asia.

Benefits
Geography
Expertise

Our team

Igor Berezovskyi
Igor BerezovskyiCEO EurMAoffice@eurma.eu
Russia, CIS, Balkans, Latin America
Thomas Rieger
Thomas RiegerCEO Solarkiosk Solutions GmbH thomas.rieger@solarkiosk.eu
Germany, Switzerland, Africa
Vasil Krumov
Vasil KrumovCEO VS Delta Investment LLPinfo@vsinvestment.com
Arab region, Asia, Greece

We work with governments,
public and private organizations

Our mission: to make this world safer. We are confident that by promoting
the medicine Avifavir we are doing a noble cause
and helping hundreds of people around the world.

Avifavir